Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners. The busiest examiner, SHOSTAK, ANDREY, is responsible for 2 pending actions, which represents a significant portion of the 5 pending office actions in the portfolio. This concentration makes SHOSTAK, ANDREY a key figure for the fund's current prosecution.
The portfolio is active across 3 distinct art units. With 4 distinct examiners operating in 3 distinct art units, multiple examiners are working within the same art unit for this organization. This distribution suggests a diverse range of technical challenges within the Biotechnology & Pharmaceuticals sector, requiring the fund to manage multiple examiner relationships and regulatory environments simultaneously. For a practitioner, success depends on reconciling the feedback from 4 distinct examiners across 3 distinct art units to resolve the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOSTAK, ANDREY | 2 | 52.4% | +61.8% |
| BEISNER, WILLIAM H | 1 | 61.9% | +29.0% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17342753 | STRESS DISORDER TRAINING | SHOSTAK, ANDREY | 73d overdue |
| 17319265 | RESILIENCE TRAINING | SHOSTAK, ANDREY | 73d overdue |
| 18574249 | SYSTEM AND METHOD FOR ISOLATING, STORING AND USING CELLS | BEISNER, WILLIAM H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17342753 | STRESS DISORDER TRAINING | SHOSTAK, ANDREY | 73d overdue |
| 17319265 | RESILIENCE TRAINING | SHOSTAK, ANDREY | 73d overdue |
| 17617043 | DEFERRED TREATMENT OF NERVE INJURIES | KOMATSU, LI N | 3d overdue |
| 18574249 | SYSTEM AND METHOD FOR ISOLATING, STORING AND USING CELLS | BEISNER, WILLIAM H | — |
| 17617095 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 3791 | 2 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574249 | SYSTEM AND METHOD FOR ISOLATING, STORING AND USING CELLS | BEISNER, WILLIAM H | 1699 | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 17617095 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | NIEBAUER, RONALD T | 1658 | §103DP | Non-Final OA | — | Pending | Dec 07, 2021 |
| 17617043 | DEFERRED TREATMENT OF NERVE INJURIES | KOMATSU, LI N | 1658 | §103Other | Final Rejection | 3d overdue | Pending | Dec 07, 2021 |
| 17342753 | STRESS DISORDER TRAINING | SHOSTAK, ANDREY | 3791 | §101§103§112DP | Final Rejection | 73d overdue | Pending | Jun 09, 2021 |
| 17319265 | RESILIENCE TRAINING | SHOSTAK, ANDREY | 3791 | §101§103§112DP | Final Rejection | 73d overdue | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center has 5 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Andrey Shostak has the most, with 2 of The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
